All In Biotech

Drug Trial Radar · NCT07459660

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML007C-MA in Adult Participants With Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

210

Planned (sponsor's estimate)

Start

Mar 25, 2026

Primary completion

Mar 2029

Study completion Mar 2029

Sponsor

Lead sponsor
MapLight TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 91 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).

Conditions

  • Psychosis Associated With Alzheimer's Disease

Interventions

  • ML-007C-MADrug

    ML-007C-MA dosed as 105/1.5 mg BID or 210/3 mg BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of long-term ML-007C-MA administration in participants with hallucinations and delusions associated with ADTime frame: From initial dose through end of treatment (up to 52 weeks)

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Anaheim, California

  • Clinical Site

    Denver, Colorado

  • Clinical Site

    Doral, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Miami Gardens, Florida

  • Clinical Site

    Orlando, Florida

  • Clinical Site

    Snellville, Georgia

  • Clinical Site

    Independence, Ohio

  • Clinical Site

    Pernik, Pernik, Bulgaria

  • Clinical Site

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.